RxDoctor Payments Data

Amber Khan, MD

Internal Medicine · Houston, TXNPI 1811108475

Payments from drug & device makers

$1,962,349in general payments, 2019–2025

Across 720 payments — averaging $2725.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$485K
  • Eli Lilly$413K
  • AbbVie$306K
  • GSK$303K
  • Sun Pharmaceutical Industries Inc.$284K
  • E.r. Squibb & Sons, L.L.C.$80K
  • plus $91K from 20 others
$73,990in research payments, 2019–2025

Across 4 payments — averaging $18,498 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$74K

What the payments were for

  • Food & beverage$1,358100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,962,349 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$959,197
Medicare patients
99
Services billed
138,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab50$584,645
Leflunomide104$5,174
Hydroxychloroquine Sulfate165$4,949
Gabapentin200$2,861
MethotrexateMethotrexate Sodium141$2,211
Celecoxib94$2,142
Duloxetine Hcl74$1,629
Prednisone311$1,389
Pregabalin12$1,369
Diclofenac Sodium43$1,245
Pilocarpine Hcl11$1,198
Chlorzoxazone23$1,198
Ibuprofen61$910
Carisoprodol18$774
Clobetasol Propionate18$706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dr.reddy's Laboratories,inc.Pregabalin$10,050$1,36912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →